D Oldenburg1, N Guberina2, B Stolte3, K Kizina3, E Stenzel2, A Radbruch2, C Kleinschnitz3, T Hagenacker3, M Forsting2, C Mönninghoff2. 1. Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Hufelandstraße 55, 45147, Essen, Germany. Denise.Oldenburg@uk-essen.de. 2. Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Hufelandstraße 55, 45147, Essen, Germany. 3. Department of Neurology, University Hospital Essen, Essen, Germany.
Abstract
PURPOSE: To examine diagnostic reference levels (DRL) and achievable doses (AD) of image-guided and size-specific dose estimates (SSDE) and organ and effective doses of CT-guided intrathecal nusinersen administration to adult patients with spinal muscular atrophy (SMA). METHODS: This study involved a total of 60 image-guided intrathecal nusinersen treatments between August 2017 and June 2018. Patient cohort comprised 14 adult patients with the following SMA types: type 2 (n = 9) and type 3 (n = 5) with a mean age of 33.6 years (age range 25-57 years). DRL, AD, SSDE, organ, and effective doses were assessed with a dose-monitoring program based on the Monte Carlo simulation techniques. RESULTS: DRL and AD for computed tomography are summarised as follows: in terms of CT-dose index (CTDIvol), DRL 56.4 mGy and AD 36.7 mGy; in terms of dose-length product (DLP), DRL 233.1 mGy cm and AD 120.1 mGy cm. DRL and AD for fluoroscopic guidance were distributed as follows: in terms of dose-area product (DAP), DRL 239.1 μGy m2 and AD 135.2 mGy cm2. Mean SSDE was 9.2 mGy. Mean effective dose of the CT-guided injections was 2.5 mSv (median 2.0 mSv, IQR 1.3-3.2 mSv). Highest organ doses in the primary beam of radiation were the small intestine 12.9 mSv, large intestine 9.5 mSv, and ovaries 3.6 mSv. CONCLUSION: Radiation exposure of SMA patients measured as DRLs is generally not higher compared with patients without SMA despite severe anatomical hazards. Dose monitoring data may allow clinicians to stratify radiation risk, identify organs at risk, and adopt measures for specific radiation dose reduction.
PURPOSE: To examine diagnostic reference levels (DRL) and achievable doses (AD) of image-guided and size-specific dose estimates (SSDE) and organ and effective doses of CT-guided intrathecal nusinersen administration to adult patients with spinal muscular atrophy (SMA). METHODS: This study involved a total of 60 image-guided intrathecal nusinersen treatments between August 2017 and June 2018. Patient cohort comprised 14 adult patients with the following SMA types: type 2 (n = 9) and type 3 (n = 5) with a mean age of 33.6 years (age range 25-57 years). DRL, AD, SSDE, organ, and effective doses were assessed with a dose-monitoring program based on the Monte Carlo simulation techniques. RESULTS: DRL and AD for computed tomography are summarised as follows: in terms of CT-dose index (CTDIvol), DRL 56.4 mGy and AD 36.7 mGy; in terms of dose-length product (DLP), DRL 233.1 mGy cm and AD 120.1 mGy cm. DRL and AD for fluoroscopic guidance were distributed as follows: in terms of dose-area product (DAP), DRL 239.1 μGy m2 and AD 135.2 mGy cm2. Mean SSDE was 9.2 mGy. Mean effective dose of the CT-guided injections was 2.5 mSv (median 2.0 mSv, IQR 1.3-3.2 mSv). Highest organ doses in the primary beam of radiation were the small intestine 12.9 mSv, large intestine 9.5 mSv, and ovaries 3.6 mSv. CONCLUSION: Radiation exposure of SMA patients measured as DRLs is generally not higher compared with patients without SMA despite severe anatomical hazards. Dose monitoring data may allow clinicians to stratify radiation risk, identify organs at risk, and adopt measures for specific radiation dose reduction.
Authors: Nika Guberina; Michael Forsting; Saravanabavaan Suntharalingam; Kai Nassenstein; Jens Theysohn; Adrian Ringelstein; Axel Wetter Journal: Rofo Date: 2016-11-15
Authors: Nika Guberina; Michael Forsting; Adrian Ringelstein; Saravanabavaan Suntharalingam; Kai Nassenstein; Jens Theysohn; Axel Wetter Journal: Eur Radiol Date: 2018-03-28 Impact factor: 5.315
Authors: Alma Osmanovic; Gresa Ranxha; Mareike Kumpe; Claudia D Wurster; Benjamin Stolte; Isabell Cordts; René Günther; Maren Freigang; Lars H Müschen; Camilla Binz; Andreas Hermann; Marcus Deschauer; Paul Lingor; Albert C Ludolph; Tim Hagenacker; Olivia Schreiber-Katz; Susanne Petri Journal: Ther Adv Neurol Disord Date: 2021-03-05 Impact factor: 6.570
Authors: Grzegorz Rosiak; Anna Lusakowska; Krzysztof Milczarek; Dariusz Konecki; Anna Fraczek; Olgierd Rowinski; Anna Kostera-Pruszczyk Journal: Neuroradiology Date: 2021-01-29 Impact factor: 2.804
Authors: Kathrin Kizina; Benjamin Stolte; Andreas Totzeck; Saskia Bolz; Michael Fleischer; Christoph Mönninghoff; Nika Guberina; Denise Oldenburg; Michael Forsting; Christoph Kleinschnitz; Tim Hagenacker Journal: Front Neurol Date: 2019-11-05 Impact factor: 4.003